The study involves repeated doses of LY3303560 given by injection for 25 weeks. The study
will examine how safe repeated doses of LY3303560 are, whether they cause side effects in
participants with mild cognitive impairment or Alzheimer's Disease, and how LY3303560 is
handled by the body and acts in the body. This study will last up to 64 weeks, not including
screening. Screening is required within 90 days prior to the start of the study.